Chip Outlook Gets Cloudier
Motley Fool Money
00:00
Challenges and Opportunities for 23andMe
This chapter delves into the hurdles faced by 23andMe post-IPO, examining issues like high costs and a significant data breach. It highlights ongoing drug development efforts, particularly in cancer treatment, and the strategic shifts initiated by the CEO to take the company private. The discussion emphasizes the lessons learned for investors regarding the importance of financial health and careful cash management in biotech investments.
Play episode from 18:14
Transcript
